Journal ArticleOPEN ACCESS

579P Methodological considerations for clinical equivalence of bevacizumab biosimilars

  • Heinzmann D
Annals of Oncology (2016) 27(suppl_9)
DOI: 10.1093/annonc/mdw603.016
N/ACitations
Citations of this article
N/AReaders
Mendeley users who have this article in their library.
Get full text

Cite

CITATION STYLE

APA

Heinzmann, D. (2016). 579P Methodological considerations for clinical equivalence of bevacizumab biosimilars. Annals of Oncology, 27(suppl_9). https://doi.org/10.1093/annonc/mdw603.016

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free